Skip to main content

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

Buy Article:

$63.00 plus tax (Refund Policy)


The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital transduction cascade that is connected with many essential cellular activities, such as growth and survival. Along with extensive pharmacological studies validating the therapeutic potential of targeting the PI3K/Akt/mTOR pathway for the treatment of cancer, kinase inhibitors targeting significant knots of this pathway including PI3K, Akt, mTOR, and 3-phosphoinositide-dependent protein kinase-1 (PDK-1) keep arising and entering clinical studies. Herein, we review the most up-to-date landscape on developing small-molecule kinase inhibitors targeting the PI3K/Akt/mTOR pathway, with emphasis on small-molecule inhibitors which have been progressed into clinical studies.

Keywords: AGC; ATM; ATP; ATR; AZD-8055; Akt; Akt/PKB; BGT226; BKM-120; CAL-101; CCI-779; CLL; COX2; Celecoxib; DNA-PK; Erlotinib; FDA; FRAP1; GDC-0941; GPCRs; MTD; Mcl-1; NHL; Nilotinib; OSI-027; PDK-1; PH; PI-103; PI3K; PI3K INHIBITORS; PIKKs; PKA; PKB; PKC; PX-866; RAD-001; RCC; Rapamycin; Raptor; Rictor; S6Ks; SCCHN; SF-1126; SGK1; SMG-1; Sunitinib; TCN-PM; TRRAP; UCN-01; Vps34; XL-765; angiogenesis; apoptosis; cancer; cancer therapy; cell growth; clinical; eIF; etoposide; immunity; kinases; mTOR; malignancies; metabolism; migration; monotherapy; motility; mutation; perifosine; proliferation; small-molecule inhibitor; transcription; translation; triciribine phosphate; tumors; xenografts

Document Type: Research Article


Publication date: December 1, 2010

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more